110 related articles for article (PubMed ID: 28382170)
61. Pulmonary metastases in differentiated thyroid cancer: efficacy of radioiodine therapy and prognostic factors.
Song HJ; Qiu ZL; Shen CT; Wei WJ; Luo QY
Eur J Endocrinol; 2015 Sep; 173(3):399-408. PubMed ID: 26104753
[TBL] [Abstract][Full Text] [Related]
62. Discovery of 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a pan-RAF inhibitor with minimal paradoxical activation and activity against BRAF or RAS mutant tumor cells.
Henry JR; Kaufman MD; Peng SB; Ahn YM; Caldwell TM; Vogeti L; Telikepalli H; Lu WP; Hood MM; Rutkoski TJ; Smith BD; Vogeti S; Miller D; Wise SC; Chun L; Zhang X; Zhang Y; Kays L; Hipskind PA; Wrobleski AD; Lobb KL; Clay JM; Cohen JD; Walgren JL; McCann D; Patel P; Clawson DK; Guo S; Manglicmot D; Groshong C; Logan C; Starling JJ; Flynn DL
J Med Chem; 2015 May; 58(10):4165-79. PubMed ID: 25965804
[TBL] [Abstract][Full Text] [Related]
63. Iodide- and glucose-handling gene expression regulated by sorafenib or cabozantinib in papillary thyroid cancer.
Ruan M; Liu M; Dong Q; Chen L
J Clin Endocrinol Metab; 2015 May; 100(5):1771-9. PubMed ID: 25768669
[TBL] [Abstract][Full Text] [Related]
64. Integrated genomic characterization of papillary thyroid carcinoma.
Cancer Genome Atlas Research Network
Cell; 2014 Oct; 159(3):676-90. PubMed ID: 25417114
[TBL] [Abstract][Full Text] [Related]
65. Efficacy and tolerability of vemurafenib in patients with BRAF(V600E) -positive papillary thyroid cancer: M.D. Anderson Cancer Center off label experience.
Dadu R; Shah K; Busaidy NL; Waguespack SG; Habra MA; Ying AK; Hu MI; Bassett R; Jimenez C; Sherman SI; Cabanillas ME
J Clin Endocrinol Metab; 2015 Jan; 100(1):E77-81. PubMed ID: 25353071
[TBL] [Abstract][Full Text] [Related]
66. Obatoclax potentiates the cytotoxic effect of cytarabine on acute myeloid leukemia cells by enhancing DNA damage.
Xie C; Edwards H; Caldwell JT; Wang G; Taub JW; Ge Y
Mol Oncol; 2015 Feb; 9(2):409-21. PubMed ID: 25308513
[TBL] [Abstract][Full Text] [Related]
67. Obatoclax overcomes resistance to cell death in aggressive thyroid carcinomas by countering Bcl2a1 and Mcl1 overexpression.
Champa D; Russo MA; Liao XH; Refetoff S; Ghossein RA; Di Cristofano A
Endocr Relat Cancer; 2014 Oct; 21(5):755-67. PubMed ID: 25012986
[TBL] [Abstract][Full Text] [Related]
68. Obatoclax induces G1/G0-phase arrest via p38/p21(waf1/Cip1) signaling pathway in human esophageal cancer cells.
Zhong D; Gu C; Shi L; Xun T; Li X; Liu S; Yu L
J Cell Biochem; 2014 Sep; 115(9):1624-35. PubMed ID: 24788582
[TBL] [Abstract][Full Text] [Related]
69. Anti-apoptotic BCL-2 proteins govern cellular outcome following B-RAF(V600E) inhibition and can be targeted to reduce resistance.
Serasinghe MN; Missert DJ; Asciolla JJ; Podgrabinska S; Wieder SY; Izadmehr S; Belbin G; Skobe M; Chipuk JE
Oncogene; 2015 Feb; 34(7):857-67. PubMed ID: 24608435
[TBL] [Abstract][Full Text] [Related]
70. Role of PI3K/Akt/mTOR and MEK/ERK pathway in Concanavalin A induced autophagy in HeLa cells.
Roy B; Pattanaik AK; Das J; Bhutia SK; Behera B; Singh P; Maiti TK
Chem Biol Interact; 2014 Mar; 210():96-102. PubMed ID: 24434245
[TBL] [Abstract][Full Text] [Related]
71. Autophagy proteins regulate ERK phosphorylation.
Martinez-Lopez N; Athonvarangkul D; Mishall P; Sahu S; Singh R
Nat Commun; 2013; 4():2799. PubMed ID: 24240988
[TBL] [Abstract][Full Text] [Related]
72. Tumor adaptation and resistance to RAF inhibitors.
Lito P; Rosen N; Solit DB
Nat Med; 2013 Nov; 19(11):1401-9. PubMed ID: 24202393
[TBL] [Abstract][Full Text] [Related]
73. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal.
Gao J; Aksoy BA; Dogrusoz U; Dresdner G; Gross B; Sumer SO; Sun Y; Jacobsen A; Sinha R; Larsson E; Cerami E; Sander C; Schultz N
Sci Signal; 2013 Apr; 6(269):pl1. PubMed ID: 23550210
[TBL] [Abstract][Full Text] [Related]
74. Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation.
Kim KB; Cabanillas ME; Lazar AJ; Williams MD; Sanders DL; Ilagan JL; Nolop K; Lee RJ; Sherman SI
Thyroid; 2013 Oct; 23(10):1277-83. PubMed ID: 23489023
[TBL] [Abstract][Full Text] [Related]
75. Molecular pathogenesis and mechanisms of thyroid cancer.
Xing M
Nat Rev Cancer; 2013 Mar; 13(3):184-99. PubMed ID: 23429735
[TBL] [Abstract][Full Text] [Related]
76. Heteroplasmy of mouse mtDNA is genetically unstable and results in altered behavior and cognition.
Sharpley MS; Marciniak C; Eckel-Mahan K; McManus M; Crimi M; Waymire K; Lin CS; Masubuchi S; Friend N; Koike M; Chalkia D; MacGregor G; Sassone-Corsi P; Wallace DC
Cell; 2012 Oct; 151(2):333-343. PubMed ID: 23063123
[TBL] [Abstract][Full Text] [Related]
77. Obatoclax, saliphenylhalamide, and gemcitabine inhibit influenza a virus infection.
Denisova OV; Kakkola L; Feng L; Stenman J; Nagaraj A; Lampe J; Yadav B; Aittokallio T; Kaukinen P; Ahola T; Kuivanen S; Vapalahti O; Kantele A; Tynell J; Julkunen I; Kallio-Kokko H; Paavilainen H; Hukkanen V; Elliott RM; De Brabander JK; Saelens X; Kainov DE
J Biol Chem; 2012 Oct; 287(42):35324-35332. PubMed ID: 22910914
[TBL] [Abstract][Full Text] [Related]
78. Anti-apoptotic MCL-1 localizes to the mitochondrial matrix and couples mitochondrial fusion to respiration.
Perciavalle RM; Stewart DP; Koss B; Lynch J; Milasta S; Bathina M; Temirov J; Cleland MM; Pelletier S; Schuetz JD; Youle RJ; Green DR; Opferman JT
Nat Cell Biol; 2012 Apr; 14(6):575-83. PubMed ID: 22544066
[TBL] [Abstract][Full Text] [Related]
79. Sodium iodide symporter for nuclear molecular imaging and gene therapy: from bedside to bench and back.
Ahn BC
Theranostics; 2012; 2(4):392-402. PubMed ID: 22539935
[TBL] [Abstract][Full Text] [Related]
80. Efficacy and survival analysis of 131I therapy for bone metastases from differentiated thyroid cancer.
Qiu ZL; Song HJ; Xu YH; Luo QY
J Clin Endocrinol Metab; 2011 Oct; 96(10):3078-86. PubMed ID: 21795449
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
